QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=B38F0E55D27DDEADFC7082A769BE0553;jsessionid=B782A917514B6CEC68A2132746CD7961;jsessionid=00EB1049F983275734CBD2CDFFA48FC4;jsessionid=A6FEA86783918E3FF5294D1E6DE4E923;jsessionid=3D1B70CDB5212EF78C4C5E6841D4ACD4 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=B38F0E55D27DDEADFC7082A769BE0553;jsessionid=B782A917514B6CEC68A2132746CD7961;jsessionid=00EB1049F983275734CBD2CDFFA48FC4;jsessionid=A6FEA86783918E3FF5294D1E6DE4E923;jsessionid=3D1B70CDB5212EF78C4C5E6841D4ACD4